Pathogenesis and management of antiphospholipid syndrome

British Journal of Haematology

Volumn 178, Issue 2, 2017, Pages 181-195

  Arachchillage, Deepa R J ^a   Laffan, Mike ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

antiphospholipid antibodies; complement; immunosuppression; pregnancy complications; thrombosis; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HEPARIN; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY; RAPAMYCIN; RITUXIMAB; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1; BETA2 GLYCOPROTEIN 1; COMPLEMENT INHIBITOR; ENZYME INHIBITOR; IMMUNOSUPPRESSIVE AGENT;

ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTICOAGULANT THERAPY; ANTIGEN BINDING; ANTIPHOSPHOLIPID SYNDROME; CLINICAL EVALUATION; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; DEEP VEIN THROMBOSIS; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; IMMUNOTHERAPY; LABORATORY DIAGNOSIS; LOW DRUG DOSE; NONHUMAN; PATHOGENESIS; PATIENT CARE; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN UNFOLDING; REVIEW; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; FEMALE; FORECASTING; IMMUNOLOGY; PREGNANCY;

ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIBODIES; BETA 2-GLYCOPROTEIN I; COMPLEMENT INACTIVATOR PROTEINS; ENZYME INHIBITORS; FEMALE; FORECASTING; HUMANS; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; PREGNANCY; PREGNANCY COMPLICATIONS; RITUXIMAB; SIROLIMUS; THROMBOSIS;

EID: 85016434559     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14632     Document Type: Review

References (127)

1. Abreu, M.M., Danowski, A., Wahl, D.G., Amigo, M.C., Tektonidou, M., Pacheco, M.S., Fleming, N., Domingues, V., Sciascia, S., Lyra, J.O., Petri, M., Khamashta, M. & Levy, R.A. (2015) The relevance of “non-criteria” clinical manifestations of antiphospholipid syndrome:14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmunity Reviews, 14, 401–414.
2. Adams, M.J., Donohoe, S., Mackie, I.J. & Machin, S.J. (2001) Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome. British Journal of Haematology, 114, 375–379.
3. Agar, C., van Os, G.M., Morgelin, M., Sprenger, R.R., Marquart, J.A., Urbanus, R.T., Derksen, R.H., Meijers, J.C. & de Groot, P.G (2010) Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood, 116, 1336–1343.
4. Agostinis, C., Durigutto, P., Sblattero, D., Borghi, M.O., Grossi, C., Guida, F., Bulla, R., Macor, P., Pregnolato, F., Meroni, P.L. & Tedesco, F (2014) A non-complement-fixing antibody to beta2 glycoprotein I as a novel therapy for antiphospholipid syndrome. Blood, 123, 3478–3487.
5. Andreoli, L., Chighizola, C.B., Banzato, A., Pons-Estel, G.J., Ramire de, J.G. & Erkan, D. (2013) Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care & Research, 65, 1869–1873.
6. Arachchillage, D.R.J. & Hillmen, P. (2015) Paroxysmal nocturnal haemoglobinuria in pregnancy. In: Disorders of Thrombosis and Haemostasis in Pregnancy (ed. by Cohen, H & O'Brien, P). pp. 327–342. 2nd edn. Springer, London.
7. Arachchillage, D.R., Efthymiou, M., Mackie, I.J., Lawrie, A.S., Machin, S.J. & Cohen, H. (2014) Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 12, 1801–1809.
8. Arachchillage, D.R., Mackie, I.J., Efthymiou, M., Chitolie, A., Hunt, B.J., Isenberg, D.A., Khamashta, M., Machin, S.J. & Cohen, H. (2016a) Rivaroxaban limits complement activation compared with warfarin in antiphospholipid syndrome patients with venous thromboembolism. Journal of Thrombosis and Haemostasis, 14, 2177–2186.
9. Arachchillage, D.R., Besser, M., Maclean, R., Baglin, T. & van Veen, J.J. (2016b) Combined factor IIa and Xa inhibitor therapy for thrombosis whilst on therapeutic anticoagulant. Thrombosis Research, 143, 137–140.
10. Arad, A., Proulle, V., Furie, R.A., Furie, B.C. & Furie, B. (2011) beta(2)-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood, 117, 3453–3459.
11. Artenjak, A., Locatelli, I., Brelih, H., Simonic, D.M., Ulcova-Gallova, Z., Swadzba, J., Musial, J., Iwaniec, T., Stojanovich, L., Conti, F., Valesini, G., Avcin, T., Cohen Tervaert, J.W., Shoenfeld, Y., Blank, M., Ambrozic, A., Sodin-Semrl, S., Bozic, B. & Cucnik, S. (2015) Immunoreactivity and avidity of IgG anti-beta2-glycoprotein I antibodies from patients with autoimmune diseases to different peptide clusters of beta2-glycoprotein I. Immunologic Research, 61, 35–44.
12. Bachmeyer, C. & Elalamy, I. (2014) Rivaroxaban as an effective treatment for recurrent superficial thrombophlebitis related to primary antiphospholipid syndrome. Clinical and Experimental Dermatology, 39, 840–841.
13. Banzato, A., Pozzi, N., Frasson, R., De Filippis, V., Ruffatti, A., Bison, E., Padayattil, S.J., Denas, G. & Pengo, V. (2011) Antibodies to Domain I of beta(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thrombosis Research, 128, 583–586.
14. Bas de Laat, H., Derksen, R.H. & de Groot, P.G. (2004) beta2-glycoprotein I, the playmaker of the antiphospholipid syndrome. Clinical Immunology, 112, 161–168.
15. Bates, S.M., Greer, I.A., Middeldorp, S., Veenstra, D.L., Prabulos, A.M. & Vandvik, P.O. (2012) VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e691S–e736S.
16. Berman, J., Girardi, G. & Salmon, J.E. (2005) TNF-alpha is a critical effector and a target for therapy in antiphospholipid antibody-induced pregnancy loss. Journal of Immunology, 174, 485–490.
17. Berman, H., Rodriguez-Pinto, I., Cervera, R., Morel, N., Costedoat-Chalumeau, N., Erkan, D., Shoenfeld, Y. & Espinosa, G. (2013) Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmunity Reviews, 12, 1085–1090.
18. Bertolaccini, M.L., Contento, G., Lennen, R., Sanna, G., Blower, P.J., Ma, M.T., Sunassee, K. & Girardi, G. (2016) Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome. Journal of Autoimmunity, 75, 30–38.
19. Betancur, J.F., Bonilla-Abadia, F., Hormaza, A.A., Jaramillo, F.J., Canas, C.A. & Tobon, G.J. (2016) Direct oral anticoagulants in antiphospholipid syndrome: a real life case series. Lupus, 25, 658–662.
20. Blank, M., Krause, I., Wildbaum, G., Karin, N. & Shoenfeld, Y. (2003) TNFalpha DNA vaccination prevents clinical manifestations of experimental antiphospholipid syndrome. Lupus, 12, 546–549.
21. Boles, J. & Mackman, N. (2010) Role of tissue factor in thrombosis in antiphospholipid antibody syndrome. Lupus, 19, 370–378.
22. Bowie, E.J., Thompson, J.H. Jr, Pascuzzi, C.A. & Owen, C.A. Jr (1963) Thrombosis in systemic lupus erythematosus despite circulating anticoagulants. Journal of Laboratory and Clinical Medicine, 62, 416–430.
23. Bramham, K., Hunt, B.J., Germain, S., Calatayud, I., Khamashta, M., Bewley, S. & Nelson-Piercy, C. (2010) Pregnancy outcome in different clinical phenotypes of antiphospholipid syndrome. Lupus, 19, 58–64.
24. Bramham, K., Thomas, M., Nelson-Piercy, C., Khamashta, M. & Hunt, B.J. (2011) First-trimester low-dose prednisolone in refractory antiphospholipid antibody-related pregnancy loss. Blood, 117, 6948–6951.
25. Branch, D.W., Dudley, D.J., Mitchell, M.D., Creighton, K.A., Abbott, T.M., Hammond, E.H. & Daynes, R.A. (1990) Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in BALB/c mice: a model for autoimmune fetal loss. American Journal of Obstetrics and Gynecology, 163, 210–216.
26. Branch, D.W., Peaceman, A.M., Druzin, M., Silver, R.K., El-Sayed, Y., Silver, R.M., Esplin, M.S., Spinnato, J. & Harger, J. (2000) A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. The Pregnancy Loss Study Group. American Journal of Obstetrics and Gynecology, 182, 122–127.
27. Breen, K.A., Seed, P., Parmar, K., Moore, G.W., Stuart-Smith, S.E. & Hunt, B.J. (2012) Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thrombosis and Haemostasis, 107, 423–429.
28. Canaud, G., Bienaime, F., Tabarin, F., Bataillon, G., Seilhean, D., Noel, L.H., Dragon-Durey, M.A., Snanoudj, R., Friedlander, G., Halbwachs-Mecarelli, L., Legendre, C. & Terzi, F. (2014) Inhibition of the mTORC pathway in the antiphospholipid syndrome. The New England Journal of Medicine, 371, 303–312.
29. Cervera, R., Rodriguez-Pinto, I., Colafrancesco, S., Conti, F., Valesini, G., Rosario, C., Agmon-Levin, N., Shoenfeld, Y., Ferrao, C., Faria, R., Vasconcelos, C., Signorelli, F. & Espinosa, G. (2014) 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmunity Reviews, 13, 699–707.
30. Cohen, H., Hunt, B.J., Efthymiou, M., Arachchillage, D.R., Mackie, I.J., Clawson, S., Sylvestre, Y., Machin, S.J., Bertolaccini, M.L., Ruiz-Castellano, M., Muirhead, N., Dore, C.J., Khamashta, M. & Isenberg, D.A. (2016) Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematology, 3, e426–e436.
31. Conley, C. & Hartmann, R.C. (1952) A hemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. Journal of Clinical Investigation, 31, 2.
32. Crowther, M.A., Ginsberg, J.S., Julian, J., Denburg, J., Hirsh, J., Douketis, J., Laskin, C., Fortin, P., Anderson, D., Kearon, C., Clarke, A., Geerts, W., Forgie, M., Green, D., Costantini, L., Yacura, W., Wilson, S., Gent, M. & Kovacs, M.J. (2003) A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. The New England Journal of Medicine, 349, 1133–1138.
33. Danowski, A., Rego, J., Kakehasi, A.M., Funke, A., Carvalho, J.F., Lima, I.V., Souza, A.W. & Levy, R.A. (2013) Guidelines for the treatment of antiphospholipid syndrome. Revista Brasileira de Reumatologia, 53, 184–192.
34. Di Simone, N., Castellani, R., Caliandro, D. & Caruso, A. (2002) Antiphospholid antibodies regulate the expression of trophoblast cell adhesion molecules. Fertility and Sterility, 77, 805–811.
35. Erkan, D., Harrison, M.J., Levy, R., Peterson, M., Petri, M., Sammaritano, L., Unalp-Arida, A., Vilela, V., Yazici, Y. & Lockshin, M.D. (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis and Rheumatism, 56, 2382–2391.
36. Erkan, D., Vega, J., Ramon, G., Kozora, E. & Lockshin, M.D. (2013) A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis and Rheumatism, 65, 464–471.
37. Erkan, D., Willis, R., Murthy, V.L., Basra, G., Vega, J., Ruiz-Limon, P., Carrera, A.L., Papalardo, E., Martinez-Martinez, L.A., Gonzalez, E.B. & Pierangeli, S.S. (2014a) A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Annals of the Rheumatic Diseases, 73, 1176–1180.
38. Erkan, D., Aguiar, C.L., Andrade, D., Cohen, H., Cuadrado, M.J., Danowski, A., Levy, R.A., Ortel, T.L., Rahman, A., Salmon, J.E., Tektonidou, M.G., Willis, R. & Lockshin, M.D. (2014b) 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmunity Reviews, 13, 685–696.
39. Erre, G.L., Pardini, S., Faedda, R. & Passiu, G. (2008) Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus, 17, 50–55.
40. Espinola, R.G., Pierangeli, S.S., Gharavi, A.E. & Harris, E.N. (2002) Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thrombosis and Haemostasis, 87, 518–522.
41. Espinosa, G., Berman, H. & Cervera, R. (2011) Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmunity Reviews, 10, 664–668.
42. Ferrara, D.E., Liu, X., Espinola, R.G., Meroni, P.L., Abukhalaf, I., Harris, E.N. & Pierangeli, S.S. (2003) Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis and Rheumatism, 48, 3272–3279.
43. Ferrara, D.E., Swerlick, R., Casper, K., Meroni, P.L., Vega-Ostertag, M.E., Harris, E.N. & Pierangeli, S.S. (2004) Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. Journal of Thrombosis and Haemostasis, 2, 1558–1563.
44. Finazzi, G., Marchioli, R., Brancaccio, V., Schinco, P., Wisloff, F., Musial, J., Baudo, F., Berrettini, M., Testa, S., D'Angelo, A., Tognoni, G. & Barbui, T. (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of Thrombosis and Haemostasis, 3, 848–853.
45. Franklin, R.D. & Kutteh, W.H. (2003) Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro. Obstetrics and Gynecology, 101, 455–462.
46. Galli, M., Comfurius, P., Maassen, C., Hemker, H.C., de Baets, M.H., van Breda-Vriesman, P.J., Barbui, T., Zwaal, R.F. & Bevers, E.M. (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet, 335, 1544–1547.
47. Galli, M., Luciani, D., Bertolini, G. & Barbui, T. (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood, 101, 1827–1832.
48. Garcia, D., Akl, E.A., Carr, R. & Kearon, C. (2013) Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood, 122, 817–824.
49. Girardi, G. (2010) Role of tissue factor in the maternal immunological attack of the embryo in the antiphospholipid syndrome. Clinical Reviews in Allergy and Immunology, 39, 160–165.
50. Girardi, G., Berman, J., Redecha, P., Spruce, L., Thurman, J.M., Kraus, D., Hollmann, T.J., Casali, P., Caroll, M.C., Wetsel, R.A., Lambris, J.D., Holers, V.M. & Salmon, J.E. (2003) Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. Journal of Clinical Investigation, 112, 1644–1654.
51. Girardi, G., Redecha, P. & Salmon, J.E. (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nature Medicine, 10, 1222–1226.
52. Glotz, D., Russ, G., Rostaing, L., Legendre, C., Chadban, S., Grinyo, J., Mamode, N., Cozzi, E., Lebranchu, Y., Sandrini, S., Couzi, L. & Marks, W. (2015) Eculizumab in Prevention of Acute Antibody-Mediated Rejection in Sensitized Deceased-Donor Kidney Transplant Recipients: 1-Year Outcomes. American Transplant Congress, Abstract number: 3039.
53. Griffiths, M.H., Papadaki, L. & Neild, G.H. (2000) The renal pathology of primary antiphospholipid syndrome: a distinctive form ofendothelial injury. QJM : Monthly Journal of the Association of Physicians, 93, 457–467.
54. Gris, J.C., Bouvier, S., Molinari, N., Galanaud, J.P., Cochery-Nouvellon, E., Mercier, E., Fabbro-Peray, P., Balducchi, J.P., Marès, P., Quéré, I. & Dauzat, M. (2012) Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood, 119, 2624–2632.
55. de Groot, P.G. & Meijers, J.C. (2011) beta(2) -Glycoprotein I: evolution, structure and function. Journal of Thrombosis and Haemostasis, 9, 1275–1284.
56. de Groot, P.G., Lutters, B., Derksen, R.H., Lisman, T., Meijers, J.C. & Rosendaal, F.R. (2005) Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. Journal of Thrombosis and Haemostasis, 3, 1993–1997.
57. Holers, V.M., Girardi, G., Mo, L., Guthridge, J.M., Molina, H., Pierangeli, S.S., Espinola, R., Xiaowei, L.E., Mao, D., Vialpando, C.G. & Salmon, J.E. (2002) Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. Journal of Experimental Medicine, 195, 211–220.
58. Ioannou, Y., Pericleous, C., Giles, I., Latchman, D.S., Isenberg, D.A. & Rahman, A. (2007) Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human beta(2)-glycoprotein I: mutation studies including residues R39 to R43. Arthritis and Rheumatism, 56, 280–290.
59. Ioannou, Y., Zhang, J.Y., Passam, F.H., Rahgozar, S., Qi, J.C., GiannakopoulosB, Qi M., Yu, P., Yu, D.M., Hogg, P.J. & Krilis, S.A. (2010) Naturally occurring free thiols within β2-glycoprotein I in vivo: nitrosylation, redox modification by endothelial cells and regulation of oxidative stress induced cell injury. Blood, 116, 1961–1970.
60. Ioannou, Y., Zhang, J.Y., Qi, M., Gao, L., Qi, J.C., Yu, D.M., Lau, H., Sturgess, A.D., Vlachoyiannopoulos, P.G., Moutsopoulos, H.M., Rahman, A., Pericleous, C., Atsumi, T., Koike, T., Heritier, S., Giannakopoulos, B. & Krilis, S.A. (2011) Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen beta2-glycoprotein I. Arthritis and Rheumatism, 63, 2774–2782.
61. Johansson, E., Forsberg, K. & Johnsson, H. (1981) Clinical and experimental evaluation ofthe thromboprophylactic effect of hydroxychloroquine sulfate after total hip replacement. Haemostasis, 10, 89–96.
62. Keeling, D., Mackie, I., Moore, G.W., Greer, I.A. & Greaves, M. (2012) Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematology, 157, 47–58.
63. Kumar, D. & Roubey, R.A. (2010) Use of rituximab in the antiphospholipid syndrome. Current Rheumatology Reports, 12, 40–44.
64. Kutteh, W.H. (1996) Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. American Journal of Obstetrics and Gynecology, 174, 1584–1589.
65. de Laat, H.B., Derksen, R.H., Urbanus, R.T., Roest, M. & de Groot, P.G (2004) beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood, 104, 3598–3602.
66. de Laat, B., Derksen, R.H., Urbanus, R.T. & de Groot, P.G. (2005) IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood, 105, 1540–1545.
67. de Laat, B., Derksen, R.H., van Lummel, M., Pennings, M.T. & de Groot, P.G. (2006) Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. Blood, 107, 1916–1924.
68. de Laat, B., Pengo, V., Pabinger, I., Musial, J., Voskuyl, A.E., Bultink, I.E., Ruffatti, A., Rozman, B., Kveder, T., de Moerloose, P., Boehlen, F., Rand, J., Ulcova-Gallova, Z., Mertens, K. & de Groot, P.G. (2009) The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. Journal of Thrombosis and Haemostasis, 7, 1767–1773.
69. Lackner, K.J. & Müller-Calleja, N. (2016) Pathogenesis of the antiphospholipid syndrome revisited: time to challenge the dogma. Journal of Thrombosis and Haemostasis, 6, 1117–1120.
70. Lambrianides, A., Carroll, C.J., Pierangeli, S.S., Pericleous, C., Branch, W., Rice, J., Latchman, D.S., Townsend, P., Isenberg, D.A., Rahman, A. & Giles, I.P. (2010) Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. Journal of Immunology, 184, 6622–6628.
71. Levine, S.R., Brey, R.L., Tilley, B.C., Thompson, J.L., Sacco, R.L., Sciacca, R.R., Murphy, A., Lu, Y., Costigan, T.M., Rhine, C., Levin, B., Triplett, D.A. & Mohr, J.P. (2004) Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA, 291, 576–584.
72. Liestol, S., Sandset, P.M., Jacobsen, E.M., Mowinckel, M.C. & Wisloff, F. (2007) Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants. British Journal of Haematology, 136, 131–137.
73. Maiti, S.N., Balasubramanian, K., Ramoth, J.A. & Schroit, A.J. (2008) β-2-glycoprotein 1-dependent macrophage uptake of apoptotic cells:binding to lipoprotein receptor-related protein receptor family members. Journal of Biological Chemistry, 283, 3761–3766.
74. Mak, A., Cheung, M.W., Cheak, A.A. & Ho, R.C. (2010) Combination of heparin and aspirin is superior to aspirin alone in enhancing live births in patients with recurrent pregnancy loss and positive anti-phospholipid antibodies: a meta-analysis of randomized controlled trials and meta-regression. Rheumatology (Oxford), 49, 281–288.
75. Malia, R.G., Kitchen, S., Greaves, M. & Preston, F.E. (1990) Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. British Journal of Haematology, 76, 101–107.
76. Manning, B.D. & Cantley, L.C. (2007) AKT/PKB signaling: navigating downstream. Cell, 129, 1261–1274.
77. Manukyan, D., Müller-Calleja, N., Jäckel, S., Luchmann, K., Mönnikes, R., Kiouptsi, K., Reinhardt, C, Jurk, K., Walter, U. & Lackner, K.J. (2016) Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice. Journal of Thrombosis and Haemostasis, 14, 1011–1020.
78. Mcneil, H.P., Simpson, R.J., Chesterman, C.N. & Krilis, S.A. (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H). Proceedings of the National Academy of Sciences of the United States of America, 87, 4120–4124.
79. Mekinian, A., Lazzaroni, M.G., Kuzenko, A., Alijotas-Reig, J., Ruffatti, A., Levy, P., Canti, V., Bremme, K., Bezanahary, H., Bertero, T., Dhote, R., Maurier, F., Andreoli, L., Benbara, A., Tigazin, A., Carbillon, L., Nicaise-Roland, P., Tincani, A. & Fain, O. (2015) The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmunity Reviews, 14, 498–502.
80. Miyakis, S., Lockshin, M.D., Atsumi, T., Branch, D.W., Brey, R.L., Cervera, R., Derksen, R.H., DE Groot, P.G., Koike, T., Meroni, P.L., Reber, G., Shoenfeld, Y., Tincani, A., Vlachoyiannopoulos, P.G. & Krilis, S.A. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). Journal of Thrombosis and Haemostasis: JTH, 4, 295–306.
81. Nayar, R. & Lage, J.M. (1996) Placental changes in a first trimester missed abortion in maternal systemic lupus erythematosus with antiphospholipid syndrome; a case report and review of the literature. Human Pathology, 27, 201–206.
82. Noel, N., Dutasta, F., Costedoat-Chalumeau, N., Bienvenu, B., Mariette, X., Geffray, L., Sene, D., Chaidi, R.B., Michot, J.M., Fain, O., Darnige, L., Ankri, A., Cacoub, P., Piette, J.C. & Saadoun, D. (2015) Safety and efficacy of oral direct inhibitors of thrombin and factor Xa in antiphospholipid syndrome. Autoimmunity Reviews, 14, 680–685.
83. Nojima, J., Kuratsune, H., Suehisa, E., Iwatani, Y. & Kanakura, Y. (2005) Acquired activated protein C resistance associated with IgG antibodies against beta2-glycoprotein I and prothrombin as a strong risk factor for venous thromboembolism. Clinical Chemistry, 51, 545–552.
84. Oku, K., Atsumi, T., Bohgaki, M., Amengual, O., Kataoka, H., Horita, T., Yasuda, S. & Koike, T. (2009) Complement activation in patients with primary antiphospholipid syndrome. Annals of the Rheumatic Diseases, 6, 1030–1035.
85. van Os, G.M., Meijers, J.C., Agar, C., Seron, M.V., Marquart, J.A., Akesson, P., Urbanus, R.T., Derksen, R.H., Herwald, H., Morgelin, M. & Groot Pg, D.E. (2011) Induction of anti-beta2 -glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. Journal of Thrombosis and Haemostasis, 9, 2447–2456.
86. Ostertag, M.V., Liu, X., Henderson, V. & Pierangeli, S.S. (2006) A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice. Lupus, 15, 358–365.
87. Out, H.J., Kooijman CD, F.A.U., Bruinse HW, F.A.U. & Derksen, R.H. (1991) Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 41, 179–186.
88. Parke, A., Maier, D., Wilson, D., Andreoli, J. & Ballow, M. (1989) Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy. Annals of Internal Medicine, 110, 495–496.
89. Pelkmans, L., Kelchtermans, H., de Groot, P.G., Zuily, S., Regnault, V., Wahl, D., Pengo, V. & de Laat, B. (2013) Variability in exposure of epitope G40-R43 of domain i in commercial anti-beta2-glycoprotein I IgG ELISAs. PLoS ONE, 8, e71402.
90. Pengo, V., Biasiolo, A., Pegoraro, C., Cucchini, U., Noventa, F. & Iliceto, S. (2005) Antibody profiles for the diagnosis of antiphospholipid syndrome. Thrombosis and Haemostasis, 93, 1147–1152.
91. Pengo, V., Biasiolo, A., Gresele, P., Marongiu, F., Erba, N., Veschi, F., Ghirarduzzi, A., Barcellona, D. & Tripodi, A. (2007) A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arteriosclerosis, Thrombosis, and Vascular Biology, 27, e309–e310.
92. Pengo, V., Ruffatti, A., Legnani, C., Gresele, P., Barcellona, D., Erba, N., Testa, S., Marongiu, F., Bison, E., Denas, G., Banzato, A., Padayattil, J.S. & Iliceto, S. (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis, 8, 237–242.
93. Pengo, V., Ruffatti, A., Legnani, C., Testa, S., Fierro, T., Marongiu, F., De Micheli, V., Gresele, P., Tonello, M., Ghirarduzzi, A., Bison, E., Denas, G., Banzato, A., Padayattil, J.S. & Iliceto, S. (2011) Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood, 118, 4714–4718.
94. Pengo, V., Ruffatti, A., Tonello, M., Cuffaro, S., Banzato, A., Bison, E., Denas, G. & Padayattil, J.S. (2015) Antiphospholipid syndrome: antibodies to Domain 1 of beta2-glycoprotein 1 correctly classify patients at risk. Journal of Thrombosis and Haemostasis, 13, 782–787.
95. Pericleous, C., Ruiz-Limon, P., Romay-Penabad, Z., Marin, A.C., Garza-Garcia, A., Murfitt, L., Driscoll, P.C., Latchman, D.S., Isenberg, D.A., Giles, I., Ioannou, Y., Rahman, A. & Pierangeli, S.S. (2015) Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of beta2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology (Oxford), 54, 722–727.
96. Pierangeli, S.S., Liu, X.W., Barker, J.H., Anderson, G. & Harris, E.N. (1995) Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome. Thrombosis and Haemostasis, 5, 1361–1367.
97. Pierangeli, S.S., Chen, P.P., Raschi, E., Scurati, S., Grossi, C., Borghi, M.O., Palomo, I., Harris, E.N. & Meroni, P.L. (2008) Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Seminars in Thrombosis and Hemostasis, 34, 236–250.
98. Rai, R., Cohen, H., Dave, M. & Regan, L. (1997) Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ, 314, 253–257.
99. Rand, J.H., Wu, X.X., Andree, H.A., Lockwood, C.J., Guller, S., Scher, J. & Harpel, P.C. (1997) Pregnancy loss in the antiphospholipid-antibody syndrome–a possible thrombogenic mechanism. The New England Journal of Medicine, 337, 154–160.
100. Rand, J.H., Wu, X.X., Quinn, A.S. & Taatjes, D.J. (2010a) The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. Lupus, 19, 460–469.
101. Rand, J.H., Wu, X.X., Quinn, A.S., Ashton, A.W., Chen, P.P., Hathcock, J.J., Andree, H.A. & Taatjes, D.J. (2010b) Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood, 115, 2292–2299.
102. Reynaud, Q., Lega, J.C., Mismetti, P., Chapelle, C., Wahl, D., Cathébras, P. & Laporte, S. (2014) Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmunity Reviews, 13, 595–608.
103. Ridker, P.M. (2009) The JUPITER trial: results, controversies, and implications for prevention. Circulation: Cardiovascular Quality and Outcomes, 2, 279–285.
104. Rodriguez-Garcia, V., Ioannou, Y., Fernandez-Nebro, A., Isenberg, D.A. & Giles, I.P. (2015) Examining the prevalence of non-criteria anti-phospholipid antibodies in patients with anti-phospholipid syndrome: a systematic review. Rheumatology (Oxford), 54, 2042–2050.
105. Romay-Penabad, Z., Carrera Marin, A.L., Willis, R., Weston-Davies, W., Machin, S., Cohen, H., Brasier, A. & Gonzalez, E.B. (2014) Complement C5-inhibitor rEV576 (coversin) ameliorates in-vivo effects of antiphospholipid antibodies. Lupus, 23, 1324–1326.
106. Ruffatti, A., Del, R.T., Ciprian, M., Bertero, M.T., Sciascia, S., Scarpato, S., Montecucco, C., Rossi, S., Caramaschi, P., Biasi, D., Doria, A., Rampudda, M., Monica, N., Fischetti, F., Picillo, U., Brucato, A., Salvan, E., Vittorio, P., Meroni, P. & Tincani, A. (2011) Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study. Annals of the Rheumatic Diseases, 70, 1083–1086.
107. Ruiz-Irastorza, G., Khamashta, M.A., Hunt, B.J., Escudero, A., Cuadrado, M.J. & Hughes, G.R. (2002) Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Archives of Internal Medicine, 162, 1164–1169.
108. Ruiz-Irastorza, G., Hunt, B.J. & Khamashta, M.A. (2007) A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis and Rheumatism, 57, 1487–1495.
109. Ruiz-Irastorza, G., Ramos-Casals, M., Brito-Zeron, P. & Khamashta, M.A. (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Annals of the Rheumatic Diseases, 69, 20–28.
110. Ruiz-Irastorza, G., Cuadrado, M.J., Ruiz-Arruza, I., Brey, R., Crowther, M., Derksen, R., Erkan, D., Krilis, S., Machin, S., Pengo, V., Pierangeli, S., Tektonidou, M. & Khamashta, M. (2011) Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus, 20, 206–218.
111. Salmon, J.E., Girardi, G. & Holers, V.M. (2003) Activation of complement mediates antiphospholipid antibody-induced pregnancy loss. Lupus, 12, 535–538.
112. Schaefer, J.K., Mcbane, R.D., Black, D.F., Williams, L.N., Moder, K.G. & Wysokinski, W.E. (2014) Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thrombosis and Haemostasis, 112, 947–950.
113. Schmidt-Tanguy, A., Voswinkel, J., Henrion, D., Subra, J.F., Loufrani, L., Rohmer, V., Ifrah, N. & Belizna, C. (2013) Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. Journal of Thrombosis and Haemostasis, 11, 1927–1929.
114. Sciascia, S., Breen, K. & Hunt, B.J. (2015) Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism. Blood Coagulation & Fibrinolysis, 26, 476–477.
115. Sciascia, S., Hunt, B.J., Talavera-Garcia, E., Lliso, G., Khamashta, M.A. & Cuadrado, M.J. (2016) The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. American Journal of Obstetrics and Gynecology, 214, 273.e1-8.
116. Shapira, I., Andrade, D., Allen, S.L. & Salmon, J.E. (2012) Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab. Arthritis and Rheumatism, 64, 2719–2723.
117. Signorelli, F., Nogueira, F., Domingues, V., Mariz, H.A. & Levy, R.A. (2016) Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clinical Rheumatology, 35, 801–805.
118. Son, M., Wypasek, E., Celinska-Lowenhoff, M. & Undas, A. (2015) The use of rivaroxaban in patients with antiphospholipid syndrome: a series of 12 cases. Thrombosis Research, 135, 1035–1036.
119. Sperber, K., Quraishi, H., Kalb, T.H., Panja, A., Stecher, V. & Mayer, L. (1993) Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells. Journal of Rheumatology, 20, 803–808.
120. The PROMISE study (Predictors of pRegnancy outcome: biomarkers In APS and Systemic lupus Erythematosus). Available at: https://clinicaltrials.gov/ct2/show/NCT00198068. (accessed 20 June 2016).
121. de la Torre, Y.M., Pregnolato, F., D'Amelio, F., Grossi, C., Di, S.N., Pasqualini, F., Nebuloni, M., Chen, P., Pierangeli, S., Bassani, N., Ambrogi, F., Borghi, M.O., Vecchi, A., Locati, M. & Meroni, P.L. (2012) Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the beta2 glycoprotein I phospholipid-binding site. Implications for human fetal loss. Journal of Autoimmunity, 38, J209–J215.
122. Tripodi, A., Chantarangkul, V., Clerici, M., Negri, B., Galli, M. & Mannucci, P.M. (2001) Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. British Journal of Haematology, 115, 672–678.
123. Willis, R., Gonzalez, E.B. & Brasier, A.R. (2015) The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome. Current Rheumatology Reports, 17, 16–0485.
124. Win, K. & Rodgers, G.M. (2014) New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. American Journal of Hematology, 89, 1017.
125. Xu, C., Mao, D., Holers, V.M., Palanca, B., Cheng, A.M. & Molina, H. (2000) A critical role for murine complement regulator crry in fetomaternal tolerance. Science, 287, 498–501.
126. Yu, P., Passam, F.H., Yu, D.M., Denyer, G. & Krilis, S. (2008) β2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminaldomain. Journal of Thrombosis and Haemostasis, 6, 1215–1223.
127. Zhang, J. & Mccrae, K.R. (2005) Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood, 105, 1964–1969.